default author photo

Kelly E. Seaton

Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology

United States

SCHOLARLY PAPERS

7

DOWNLOADS

583

TOTAL CITATIONS

0

Scholarly Papers (7)

1.

Fixed Dosing Versus Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults: A Pharmacokinetics Modeling Study

Number of pages: 23 Posted: 14 Jan 2025
Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, FHI 360 (Family Health International), HPTN Leadership and Operations Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Fred Hutchinson Cancer Research Center, Harvard University - Brigham and Women’s Hospital, University of North Carolina (UNC) at Chapel Hill - School of Medicine, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Kelly Government Solutions, Columbia University - Aaron Diamond AIDS Research Center, Columbia University - Irving Medical Center, Emory University - School of Medicine, University of North Carolina (UNC) at Chapel Hill, Harvard University - Beth Israel Deaconess Medical Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Emory University - Division of Infectious Diseases, University of KwaZulu-Natal - Centre for the AIDS Programme of Research in South Africa (CAPRISA), George Washington University - School of Medicine and Health Sciences, National Institutes of Health, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, National Institutes of Health - Vaccine Research Center and Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology
Downloads 109 (645,052)

Abstract:

Loading...

HIV prevention, dosing strategy, exponent of body weight, two-compartment, population pharmacokinetics model, variability in exposure

2.

Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition

Number of pages: 35 Posted: 18 Oct 2022
Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University, Duke University - School of Medicine, Duke University - School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Independent, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Washington, University of Cape Town (UCT) - Institute of Infectious Disease and Molecular Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Washington - Department of Biostatistics, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, FHI 360 (Family Health International), Via Libre CRS, University of California, Los Angeles (UCLA) - Department of Medicine, Wits Health Consortium - Perinatal HIV Research Unit (PHRU), University of Cape Town (UCT) - Department of Medicine, University of Pennsylvania, Asociacion Civil Impacta Salud y Educacion, Emory University - School of Medicine, San Miguel Clinical Research Center - Asociacion Civil Impacta Salud y Educacion, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, National Institute for Communicable Diseases of the National Health Laboratory Service, Duke University - Duke Human Vaccine Institute, University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division and Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology
Downloads 98 (699,467)

Abstract:

Loading...

body weight, HIV, prevention, broadly neutralizing antibodies, monoclonal antibody, pharmacokinetics

3.

Lower SARS-CoV-2-Specific Humoral Immunity in People Living With HIV-1 Recovered From Symptomatic Non-Hospitalized COVID-19

Number of pages: 44 Posted: 04 Jan 2022
affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - School of Medicine, affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University, affiliation not provided to SSRN, Duke University - Duke Human Vaccine Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Pennsylvania - Department of Medicine, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology and affiliation not provided to SSRN
Downloads 95 (715,072)

Abstract:

Loading...

HIV-1, PLWH, People Living with HIV, SARS-CoV-2, COVID-19, humoral immunity, antibody, antibody isotype, antibody subclass, ACE-2 blocking, ADCP, antibody dependent phagocytosis, Multiplex assay, Meso Scale Discovery, IgG, IgG1, IgG3, IgA, CoVPN

4.

Safety, Pharmacokinetics, and Neutralization Activity of PGDM1400LS, VRC07-523-LS, and PGT121.414.LS Infused Intravenously or Subcutaneously: A Phase 1 Randomized Trial (HVTN 140/HPTN 101 Part B)

Number of pages: 37 Posted: 18 Jul 2025
University of KwaZulu-Natal - Centre for the AIDS Programme of Research in South Africa (CAPRISA), Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, HPTN Leadership and Operations Center, Duke University, Duke University, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center, National Institutes of Health, Kelly Government Solutions, University of North Carolina (UNC) at Chapel Hill - Division of Chemical Biology and Medicinal Chemistry, Fred Hutchinson Cancer Research Center, Johns Hopkins University, FHI 360, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Vanderbilt University - Division of Infectious Diseases, San Francisco Department of Health, University of the Witwatersrand, University of the Witwatersrand - Reproductive Health and HIV Research Unit (RHRU), University of Cape Town, Wits Health Consortium - Perinatal HIV Research Unit (PHRU), University of Zimbabwe - Faculty of Medicine and Health Sciences, University of Zimbabwe, University of Zimbabwe, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, Dartmouth College, Dartmouth College - Thayer School of Engineering, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases, Harvard Medical School - Beth Israel Deaconess Medical Center - Center for Virology and Vaccine Research, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Duke University - Duke Human Vaccine Institute, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, George Washington University - School of Medicine and Health Sciences, Emory University - Division of Infectious Diseases and Independent
Downloads 83 (783,685)

Abstract:

Loading...

HIV, monoclonal antibodies, passive immunization, PGDM1400LS, VRC07-523LS, PGT121.414.LS

5.

Safety, Pharmacokinetics, and Immunogenicity of Combination Long-Acting Broadly Neutralizing Anti-HIV-1 Antibodies 3BNC117-LS and 10-1074-LS in People with and without HIV

Number of pages: 43 Posted: 09 Oct 2025
Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Rockefeller University, Fred Hutchinson Cancer Research Center, Rockefeller University - Laboratory of Molecular Immunology, Rockefeller University, Rockefeller University, Dartmouth College, Rockefeller University, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Duke University, Rockefeller University, Rockefeller University, Rockefeller University, International AIDS Vaccine Initiative, Dartmouth College - Thayer School of Engineering, Harvard University - Beth Israel Deaconess Medical Center, Duke University, Fred Hutchinson Cancer Research Center, Rockefeller University - Laboratory of Molecular Immunology and Rockefeller University - Laboratory of Molecular Immunology
Downloads 79 (823,616)

Abstract:

Loading...

HIV, Broadly neutralizing antibodies, Pharmacokinetics

6.

Baseline Host Determinants of Robust Human HIV-1 Vaccine- Induced Immune Responses: A Meta-Analysis of 26 Vaccine Regimens

Number of pages: 43 Posted: 11 Apr 2022
Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of KwaZulu-Natal - Centre for the AIDS Programme of Research in South Africa, University of Manitoba, Instituto Nacional de Saude, South African Medical Research Council, Aurum Institute, University of California, San Francisco (UCSF) - Department of Epidemiology and Biostatistics, Emory University - School of Medicine, University of Cape Town (UCT) - Desmond Tutu HIV Centre, University of Rochester - School of Medicine and Dentistry, University of North Carolina (UNC) at Chapel Hill - UNC-Project Malawi, University of Alabama at Birmingham - Heersink School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, University of Rochester - School of Medicine and Dentistry, University of Alabama at Birmingham, Fenway Community Health - The Fenway Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Independent and affiliation not provided to SSRN
Downloads 77 (830,555)

Abstract:

Loading...

Baseline characteristics, SuperLearner, Variable importance measurements, Vaccine response heterogeneity, Antibody, CD4+ T cell

7.

DNA electroporation of HIV Env elicits unique pattern of immune responses compared to other methods of immunogen delivery, including robust CD8+ responses and memory B cell responses with muted serum antibody levels when boosted with recombinant protein

Number of pages: 32 Posted: 01 Oct 2025
Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Alabama at Birmingham, affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, affiliation not provided to SSRN, Duke University - Duke Human Vaccine Institute, Duke University, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Department of Surgery, The Scripps Research Institute - Department of Integrative Structural and Computational Biology, The Scripps Research Institute - Department of Integrative Structural and Computational Biology, The Scripps Research Institute - Department of Integrative Structural and Computational Biology, The Scripps Research Institute, National Institutes of Health, affiliation not provided to SSRN, Columbia University, Vanderbilt University - Division of Infectious Diseases, affiliation not provided to SSRN, Wistar Institute, Wistar Institute, Wistar Institute, Wistar Institute, affiliation not provided to SSRN, Government of the United States of America - Vaccine Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division and University of Pennsylvania - Vaccine Center
Downloads 42 (1,157,785)

Abstract:

Loading...

HIV-1 vaccine, DNA vaccine, Clinical Trial, neutralizing antibodies, B cell response, CD8+ T cell response